SCHEMBL15059092

SCHEMBL15059092

CCN(CC)C(=O)C(F)(F)Oc1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ PPARG P37231 3/20 0.39
▸ PPARA Q07869 3/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CACNA1B Q00975 1/20 0.38
▸ TSPO P30536 1/20 0.38
▸ MAOB P27338 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ CETP P11597 1/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ OPRD1 P41143 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15057124 0.84 HPGD (0.45) RIPK1HPGDPPARGPPARAMRGPRX4
SCHEMBL15076095 0.83 CETP (0.39) HPGDPPARGPPARAMRGPRX4SLC6A2
SCHEMBL15058493 0.79 HPGD (0.47) RIPK1HPGDPPARGPPARAMRGPRX4
SCHEMBL15546762 0.78 POLB (0.49) PPARGPPARAMRGPRX4ABCB11TSHR
SCHEMBL23519098 0.77 PPARG (0.45) HPGDPPARGPPARAMRGPRX4NPC1
SCHEMBL8209276 0.76 MEN1 (0.61) MAOBNPC1RAB9ATSHRKMT2A
SCHEMBL15545838 0.75 KCNN4 (0.50) HPGDPPARGPPARAMAOBKCNH2
SCHEMBL15076071 0.72 CETP (0.41) HPGDPPARGPPARAMRGPRX4MAOB
SCHEMBL7988059 0.70 PPARA (0.61) PPARGPPARAABCB11TSHR
SCHEMBL3373353 0.69 PPARA (0.54) PPARGPPARACYP2D6TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9518045-B2 Process for manufacturing benzoxazinones BASF SE (DE) 2016-12-13 — — US disclosed
US-9518045-B2 Process for manufacturing benzoxazinones BASF SE (DE) 2016-12-13 — — US disclosed
US-9518045-B2 Process for manufacturing benzoxazinones BASF SE (DE) 2016-12-13 — — US disclosed
EP-2885281-B1 CARBAMAT-BENZOXAZINONES USEFUL FOR PREPARING TRIAZIN-BENZOXAZINONES BASF SE (DE) 2016-12-07 — — EP disclosed
EP-2794554-B1 PROCESS FOR MANUFACTURING ARYLOXYACETAMIDES BASF SE (DE) 2016-08-17 — — EP disclosed
EP-2794554-B1 PROCESS FOR MANUFACTURING ARYLOXYACETAMIDES BASF SE (DE) 2016-08-17 — — EP disclosed
EP-2885296-B1 PROCESS FOR MANUFACTURING BENZOXAZINONES BASF SE (DE) 2016-06-29 — — EP disclosed
EP-2885296-B1 PROCESS FOR MANUFACTURING BENZOXAZINONES BASF SE (DE) 2016-06-29 — — EP disclosed
US-9365495-B2 Process for manufacturing aryloxyacetamides BASF SE (DE) 2016-06-14 — — US disclosed
US-9365495-B2 Process for manufacturing aryloxyacetamides BASF SE (DE) 2016-06-14 — — US disclosed
US-20150119572-A1 Process for Manufacturing Aryloxyacetamides BASF SE (DE) 2015-04-30 — — US disclosed
US-20150119572-A1 Process for Manufacturing Aryloxyacetamides BASF SE (DE) 2015-04-30 — — US disclosed
US-20150119572-A1 Process for Manufacturing Aryloxyacetamides BASF SE (DE) 2015-04-30 — — US disclosed
US-9000152-B2 Process for manufacturing triazinon-benzoxazinones BASF SE (DE) 2015-04-07 — — US disclosed
US-20140357861-A1 PROCESS FOR MANUFACTURING BENZOXAZINONES BASF SE (DE) 2014-12-04 — — US disclosed
EP-2794554-A1 PROCESS FOR MANUFACTURING ARYLOXYACETAMIDES BASF SE (DE) 2014-10-29 — — EP disclosed
US-20140316131-A1 PROCESS FOR MANUFACTURING TRIAZINON-BENZOXAZINONES BASF SE (DE) 2014-10-23 — — US disclosed
WO-2014026928-A1 PROCESS FOR MANUFACTURING BENZOXAZINONES BASF SE (DE) 2014-02-20 — — WO disclosed
WO-2014026893-A1 CARBAMAT-BENZOXAZINONES BASF SE (DE) 2014-02-20 — — WO disclosed
WO-2013092850-A1 PROCESS FOR MANUFACTURING ARYLOXYACETAMIDES BASF SE (DE) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357861-A1 PROCESS FOR MANUFACTURING BENZOXAZINONES XDH, CYP4X1, CYP3A5 RIPK1 4292/4885HPGD 115/4885PPARG 1384/4885
US-20150119572-A1 Process for Manufacturing Aryloxyacetamides AADAC, CYP2E1, CYP1A2 RIPK1 4884/4885HPGD 302/4885PPARG 830/4885
US-20140316131-A1 PROCESS FOR MANUFACTURING TRIAZINON-BENZOXAZINONES CYP2B6, UGT1A6, UGT2B17 RIPK1 3876/4885HPGD 732/4885PPARG 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback